Format

Send to

Choose Destination
Cell Metab. 2015 Jul 7;22(1):164-74. doi: 10.1016/j.cmet.2015.05.010. Epub 2015 May 19.

GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration.

Author information

1
Novartis Institutes for Biomedical Research, 100 Technology Square, Cambridge, MA 02139, USA.
2
Novartis Institutes for Biomedical Research, Forum 1, Novartis Campus, 4056 Basel, Switzerland.
3
Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
4
Novartis Institutes for Biomedical Research, 100 Technology Square, Cambridge, MA 02139, USA. Electronic address: david.glass@novartis.com.

Abstract

Age-related frailty may be due to decreased skeletal muscle regeneration. The role of TGF-β molecules myostatin and GDF11 in regeneration is unclear. Recent studies showed an age-related decrease in GDF11 and that GDF11 treatment improves muscle regeneration, which were contrary to prior studies. We now show that these recent claims are not reproducible and the reagents previously used to detect GDF11 are not GDF11 specific. We develop a GDF11-specific immunoassay and show a trend toward increased GDF11 levels in sera of aged rats and humans. GDF11 mRNA increases in rat muscle with age. Mechanistically, GDF11 and myostatin both induce SMAD2/3 phosphorylation, inhibit myoblast differentiation, and regulate identical downstream signaling. GDF11 significantly inhibited muscle regeneration and decreased satellite cell expansion in mice. Given early data in humans showing a trend for an age-related increase, GDF11 could be a target for pharmacologic blockade to treat age-related sarcopenia.

Comment in

PMID:
26001423
PMCID:
PMC4497834
DOI:
10.1016/j.cmet.2015.05.010
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center